Knight Therapeutics Stock Investor Sentiment

KHTRF Stock  USD 3.84  0.01  0.26%   
Roughly 54% of Knight Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Knight Therapeutics pink sheet suggests that many investors are impartial at this time. The current market sentiment, together with Knight Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Knight Therapeutics stock news signals to limit their universe of possible portfolio assets.
Knight Therapeutics pink sheet news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Knight daily returns and investor perception about the current price of Knight Therapeutics as well as its diversification or hedging effects on your existing portfolios.
  
over a year ago at news.google.com         
Notice of Knight Therapeutics Second Quarter 2023 Results Conference Call - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Gu...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in...
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews ... - Digital Journal
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
60 Degrees Pharmaceuticals Announces Closing of Initial Public ... - Kentucky Today
Google News at Macroaxis
over a year ago at news.google.com         
US FTC chair to face questions on court losses in congressional hearing - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Knight Announces Normal Course Issuer Bid - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Biden names two Republican nominees for FTC commissioner ... - Investing.com
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx, Inc. Reports Employment Inducement Grants - Ardelyx - Benzinga
Google News at Macroaxis
over a year ago at news.google.com         
Leishmaniasis Market Analysis of Epidemiology, Pipeline Therapies, and Key Companies Companies Aurob...
Google News at Macroaxis
over a year ago at news.google.com         
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Pro...
Google News at Macroaxis
over a year ago at news.google.com         
Knight to Present at the Jefferies 2023 Healthcare Conference in New York City - Yahoo Finance
Google News at Macroaxis
over a year ago at news.google.com         
Ardelyx to Present at the Jefferies 2023 Healthcare Conference - Marketscreener.com
Google News at Macroaxis
over a year ago at news.google.com         
Samira Sakhia Bought 12 percent More Shares In Knight Therapeutics - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Knight Therapeutics that are available to investors today. That information is available publicly through Knight media outlets and privately through word of mouth or via Knight internal channels. However, regardless of the origin, that massive amount of Knight data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Knight Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Knight Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Knight Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Knight Therapeutics alpha.

Knight Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Knight Pink Sheet analysis

When running Knight Therapeutics' price analysis, check to measure Knight Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Knight Therapeutics is operating at the current time. Most of Knight Therapeutics' value examination focuses on studying past and present price action to predict the probability of Knight Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Knight Therapeutics' price. Additionally, you may evaluate how the addition of Knight Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Transaction History
View history of all your transactions and understand their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals